SCHEMBL4124542

SCHEMBL4124542

Cc1ccc(NC(=O)Nc2ccc(-n3cnc(Cl)c3Cl)cc2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 3/20 0.71
RAB9A P51151 8/20 0.50
SMN1; SMN2 Q16637 5/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
NPC1 O15118 7/20 0.48
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPK14 Q16539 1/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
F10 P00742 1/20 0.44
PRSS1 P07477 1/20 0.44
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4109941 0.87 PTK2 (0.63) PTK2RAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL13239824 0.87 PTK2 (0.56) PTK2RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL4141522 0.84 EPHX2 (0.58) PTK2RAB9AMKNK1MKNK2NPC1
SCHEMBL13481171 0.83 MKNK1 (0.67) PTK2RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL4112679 0.80 PTK2 (0.50) PTK2RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL4132655 0.75 EPHX2 (0.61)
SCHEMBL4126438 0.74 KDR (0.55) PTK2RAB9AMEN1HTTKMT2A
SCHEMBL1574456 0.73 MKNK1 (0.57) PTK2RAB9ASMN1; SMN2MKNK1MKNK2
SCHEMBL1275920 0.73 ALDH1A1 (0.70) RAB9ASMN1; SMN2L3MBTL1NPC1MEN1
SCHEMBL10134015 0.72 MKNK1 (0.56) PTK2MKNK1MKNK2F10PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 PTK2 4815/4885RAB9A 815/4885SMN1; SMN2 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.